P2.15-09 the Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients With Advanced NSCLC in 2017

Journal of Thoracic Oncology- United States

doi 10.1016/j.jtho.2018.08.1450

Full Text

Abstract

Available in

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

MA18.02 the Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn86 - Validation of the Impact of Treatment Evolution in Non-Small Cell Lung Cancer (Nsclc) Model (Iten): A Discrete Event Patient Simulation

Value in Health

Occupational Health

English

P2.15-16 Clinical Economic Impact of Improved Genotyping in Patients With Advanced Non-Small Cell Lung Adenocarcinoma (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.15-18 Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.17-09 Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-09 Impact of Urban or Rural Residence on Overall Survival for Patients With Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.15-31 the Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management

English